ASTELLAS PHARMA chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 733.58
Dividend & Yield60.00¥ (3.01%)
Beta 0.56
Market capitalization 3.58T
Operating cash flow 266.19B
ESG Scores 21.2

Company description

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Sector: Healthcare - Industry: Drug Manufacturers—General

Financial data

Financial Statements

Cashflow Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Change To Liabilities 40.83B -21.36B -51.57B -10.1B
Total Cashflows From Investing Activities -41.76B -389.79B -81.89B -62.41B
Net Borrowings 326B 326B -126B -60B
Total Cash From Financing Activities -233.68B 181.06B -229.48B -216.3B
Change To Operating Activities 20M -10.4B 47.39B -16.64B
Issuance Of Stock
Net Income 222.26B 195.41B 120.59B 124.09B
Change In Cash -20.66B 7.32B 7.74B -10.14B
Effect Of Exchange Rate -2.12B -5.94B 12.27B 11.12B
Total Cash From Operating Activities 258.63B 222B 306.84B 257.44B
Depreciation 63.46B 66.4B 72.65B 79.68B
Change To Account Receivables -25.64B -16.39B 22.16B -8B
Other Cashflows From Financing Activities -1.17B -18.51B -18.16B -20.34B
Change To Netincome -63.52B -35.56B 73.2B 31.56B
Capital Expenditures -25.19B -41.27B -31.38B -30.74B

Income Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Research Development 208.68B 224.23B 224.49B 246.01B
Income Before Tax 248.97B 245.35B 145.32B 156.89B
Net Income 222.26B 195.41B 120.59B 124.09B
Selling General Administrative 490.26B 499.3B 504.32B 548.84B
Gross Profit 1.01T 1.02T 1T 1.04T
Ebit 282.42B 267.48B 250.93B 218.15B
Operating Income 282.42B 267.48B 250.93B 218.15B
Interest Expense -2.23B -2.23B -2.12B -2.31B
Income Tax Expense 26.7B 49.94B 24.73B 32.8B
Total Revenue 1.31T 1.3T 1.25T 1.3T
Cost Of Revenue 292.05B 276.74B 246.06B 253.01B
Total Other Income ExpenseNet -33.45B -22.13B -105.61B -61.26B
Net Income From Continuing Ops 222.26B 195.41B 120.59B 124.09B
Net Income Applicable To Common Shares 222.26B 195.41B 120.59B 124.09B

Balance Sheet Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Total Liabilities 639.25B 1.03T 887.51B 872.09B
Total Stockholder Equity 1.26T 1.29T 1.39T 1.46T
Other Current Liabilities 234.23B 206.37B 206.6B 262.39B
Total Assets 1.9T 2.32T 2.27T 2.33T
Common Stock 103B 103B 103B 103B
Other Current Assets 16.48B 6.57B 19.66B 29B
Retained Earnings 991.96B 905.85B 953.29B 944.26B
Treasury Stock -13.86B 102.81B 152B 233.58B
Cash 311.07B 318.39B 326.13B 315.99B
Total Current Liabilities 495.76B 798.71B 592.37B 687.41B
Other Stockholder Equity 150.77B 109.99B 167.37B 247.51B
Property, Plant, and Equipment 173.48B 268.6B 264.62B 269.04B
Total Current Assets 857.16B 867.51B 872.59B 923.35B
Net Tangible Assets 602.83B 283.15B 450.68B 533.85B
Net Receivables 362.74B 370.6B 357.16B 404B
Accounts Payable 185.28B 171.95B 124.78B 130.74B


Insider Transactions

Here are the insider transactions of stock shares related to ASTELLAS PHARMA:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to ASTELLAS PHARMA. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on ASTELLAS PHARMA

Here is the result of two systematic investment strategies applied to ASTELLAS PHARMA. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on ASTELLAS PHARMA

The following chart shows the equity curve of the two systematic investment strategies applied to ASTELLAS PHARMA:

ASTELLAS PHARMA automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 15.2% on the backtest period.

Performance at glance

Performance

15.2 %

Latent gain

1642.0 ¥

Invested capital

10800.5 ¥

Annualized return

3.62 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on ASTELLAS PHARMA

This is the result of two momentum investment strategies applied to ASTELLAS PHARMA. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on ASTELLAS PHARMA

The following chart shows all the entries opened by the momentum investment system on ASTELLAS PHARMA:

ASTELLAS PHARMA momentum entries
  • The first momentum investment strategy would give 24.61% of return on ASTELLAS PHARMA. That represents 2106.0¥ of latent gain with 8559.0¥ of employed capital.
  • The second momentum investment strategy would give 18.65% of return on ASTELLAS PHARMA. That represents 1676.5¥ of latent gain with 8988.5¥ of employed capital.
Performance at glance (1Q Momentum)

Performance

24.61 %

Latent gain

2106.0 ¥

Invested capital

8559.0 ¥

Annualized return

4.31 %
Performance at glance (2Q Momentum)

Performance

18.65 %

Latent gain

1676.5 ¥

Invested capital

8988.5 ¥

Annualized return

5.01 %

Momentum equity curve on ASTELLAS PHARMA

The following chart shows the equity curve of the two momentum strategies applied to ASTELLAS PHARMA:

ASTELLAS PHARMA momentum equity

Note: the dividends potentially given by ASTELLAS PHARMA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on ASTELLAS PHARMA

The following chart shows the employed capital evolution of the two momentum strategies on ASTELLAS PHARMA since the beginning:

ASTELLAS PHARMA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250¥, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000¥.


Buy the dip strategy result on ASTELLAS PHARMA

Buy the dip entry openings on ASTELLAS PHARMA

ASTELLAS PHARMA

The performance achieved by the robo-advisor on ASTELLAS PHARMA is 9.49%. That represents 924.0$ of latent gain with 9741.0¥ of employed capital. The following chart shows ASTELLAS PHARMA stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of ASTELLAS PHARMA, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

9.49 %

Latent gain

924.0 ¥

Invested capital

9741.0 ¥

Annualized return

4.31 %

Equity curve of the strategy applied to ASTELLAS PHARMA

The following chart shows the result of the investment strategy applied to ASTELLAS PHARMA:

ASTELLAS PHARMA

Note: the dividends potentially given by ASTELLAS PHARMA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on ASTELLAS PHARMA

The following chart shows the employed capital evolution since the beginning of the investment strategy on ASTELLAS PHARMA:

ASTELLAS PHARMA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on ASTELLAS PHARMA

In this section, I will compare the three previous investment strategies applied to ASTELLAS PHARMA.

Equity curve comparison on ASTELLAS PHARMA

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

ASTELLAS PHARMA investment strategy comparison

Employed capital comparison on ASTELLAS PHARMA

ASTELLAS PHARMA investment comparison

Performance comparison on ASTELLAS PHARMA

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 15.2% 1642.0¥ 10800.5¥ 3.62%
Momentum 1 quarter 24.61% 2106.0¥ 8559.0¥ 6.21%
Momentum 2 quarters 18.65% 1676.5¥ 8988.5¥ 5.01%
Non-directional 9.49% 924.0¥ 9741.0¥ 4.31%
Annualized return comparison

Automatic investment

3.62 %

Momentum 1Q

5.01 %

Momentum 2Q

5.01 %

Non-directional

4.31 %

Correlated stocks

Here are the most positively and negatively correlated stocks with ASTELLAS PHARMA:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between ASTELLAS PHARMA and the other stocks. There may be false positives or some missing correlated stocks. If the price of ASTELLAS PHARMA does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name ASTELLAS PHARMA
Country Japan
City Tokyo
Address 2-5-1, Nihonbashi-Honcho
Phone 81 3 3244 3000
Website www.astellas.com
FullTime employees 14522
Industry Drug Manufacturers—General
Sector Healthcare
Exchange XTKS
Ticker 4503.XTKS
Market www.jpx.co.jp

ASTELLAS PHARMA ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 1.8
Peer Environment Performance 2.0330864197531
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 12.2
Peer Social Performance 14.299012345679
Social Percentile unknown
Highest Controversy 2
Peer Highest Controversy Performance 1.8780487804878
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic yes
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Business Ethics Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 7.3
Peer Governance Performance 8.8141975308642
Governance Percentile unknown

ESG at glance
Total ESG Scores: 21.2
Environment Score: 1.8
Social Score: 12.2
Governance Score: 7.3

ESG Performance: AVG_PERF

Peer Group: Pharmaceuticals

Peer Esg Score Performance: 25.306097560976

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 29